Biden administration’s limit on drug industry middlemen backfires, pharmacists say

The conventional wisdom of giving long-term beta-blockers for secondary prevention after myocardial infarction (MI), in the absence of another clinical indication, was questioned by a

Mod­er­na laid out its ex­pec­ta­tions for sev­er­al vac­cine mar­kets Wednes­day morn­ing at an in­vestor event as it con­tin­ues mov­ing through its “year of tran­si­tion.” A

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes